Biohaven (NYSE:BHVN) Shares Down 7.4% - What's Next?Market Beat·Aug 27 at 11:00 AMBHVN-4.40%BLK-0.26%
SK inks $795m Biohaven epilepsy deal, entering potassium channel opener racePharmaceutical Technology·Aug 27 at 08:40 AMBHVN-4.40%03121-0.15%
Delaware court enters USD 4 million judgment for Biohaven, Yale in trade secret case against RA Capital, AvilarPUBT·Aug 26 at 04:52 AMBHVN-4.40%
05:29 ETSK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'prnewswire·Aug 26 at 04:31 AMBHVN-4.40%03121-0.15%
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy | BHVN Stock NewsStockTitan·Aug 25 at 05:36 PMBHVN-4.40%03121-0.15%
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University | BHVN Stock NewsStockTitan·Aug 25 at 07:41 AMBHVN-4.40%
Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement?Simplywall·Aug 23 at 02:37 PMBHVN-4.40%
HC Wainwright Decreases Earnings Estimates for BiohavenMarket Beat·Aug 21 at 07:42 AMBHVN-4.40%UBS+0.99%
Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LPMarket Beat·Aug 16 at 03:48 AMBHVN-4.40%
Biohaven: Pipeline Promise Offset by Cash Constraints and Clinical Uncertainty; Hold Rating Reiterated with Unchanged $10 Price TargetTip Ranks·Aug 12 at 12:15 PMBHVN-4.40%
Biohaven: Broad Late-Stage Pipeline Supports Buy Rating and Unchanged $21 Price TargetTip Ranks·Aug 11 at 06:06 AMBHVN-4.40%
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results | BHVN Stock NewsStockTitan·Aug 10 at 07:02 AMBHVN-4.40%
